This is a Phase 1 study to evaluate the safety and tolerability of Single ascending oral doses of CV-02 in healthy adult subjects. CV-02 is being developed for the possible treatment possible treatment for multiple sclerosis.

Frontage Clinical Services prioritizes the safety and well-being of our study participants, our employees, and visitors to our clinic. As such, we have incorporated additional policies and procedures, as recommended by the CDC.

Application for Clinical Research Study

This is a Phase 1 study to evaluate the safety and tolerability of Single ascending oral doses of CV-02 in healthy adult subjects. CV-02 is being developed for the possible treatment possible treatment for multiple sclerosis.

Your information will be used solely for research recruitment purposes by our research team and will not be shared externally. All submissions are stored securely in accordance with HIPAA and Good Clinical Practice (GCP) standards.

Please fill out all required fields.